Evaluation of Effectiveness and Safety of Dexmedetomidine in non-Mechanically Ventilated COVID-19 Critically ill Patients: A Multicentre Cohort Study
Ahmed Basilim,Khalid Eljaaly,Ohoud Aljuhani,Ghazwa B. Korayem,Ali F. Altebainawi,Wadha J. Aldhmadi,Abdulrahman Alissa,Mashael AlFaifi,Abdullah F. Alharthi,Ramesh Vishwakarma,Reem alqahtani,Ghaida D. Alahmari,Afnan M. Ibn Khamis,Abeer A. Alenazi,Aisha Alharbi,Lulwa Alfaraj,Yasser F. Alshammari,Marwah I. Abdulqader,Mada B. Alharbi,Bayan M. Alanazi,Atheer E. Alhamazani,Khalid Al Sulaiman
DOI: https://doi.org/10.1177/08850666241268498
2024-11-25
Journal of Intensive Care Medicine
Abstract:Journal of Intensive Care Medicine, Ahead of Print. Background: Dexmedetomidine (DEX) is a highly favored sedative agent in critically ill patients owing to its anxiolytic and analgesic properties, lower risk of delirium, and minimal respiratory depression. Additionally, DEX exhibits anti-inflammatory properties, which have prompted its use in managing COVID-19 patients to mitigate cytokine storm and multi-organ dysfunction. Thus, this study aims to evaluate the safety and effectiveness of DEX use in critically ill patients with COVID-19. Method: This multicenter, retrospective cohort study included adult patients with confirmed COVID-19 who were admitted to the ICUs and did not require invasive mechanical ventilation (MV). Patients were categorized into two groups based on receiving DEX use within 72 h of ICU admission. The primary outcome was respiratory failure requiring invasive MV; other outcomes were considered secondary. Results: A total of 155 patients were included in the study after propensity matching. DEX did not reduce respiratory failure requiring invasive MV (HR 0.66; 95% CI (0.28, 1.53), P = .33). However, the time for invasive MV was statistically significantly shorter in the DEX group compared with the control group (beta coefficient (95%CI): - 1.05 (−2.03, −0.07), P = .03). In contrast, ICU and hospital Length of stay (LOS) were not statistically significant compared to the control group (beta coefficient 0.04 (95% CI −0.29, 0.38), P = .80, and beta coefficient - 0.03 (95% CI −0.33, 0.26), P = .81, respectively). In addition, the 30-day and in-hospital mortality rates were similar between the two groups (HR 1.1; 95% CI 0.97, 1.20, P = .14, and HR 1.01; 95% CI 0.95, 1.06, P = .90, respectively). Conclusion: Dexmedetomidine did not appear to lower the risk of respiratory failure necessitating invasive mechanical ventilation in critically ill patients. However, the mean time for invasive mechanical ventilation was shorter in the DEX group. Future interventional studies are required to confirm our findings.
critical care medicine